Cargando…

D‐dimer testing in clinical practice in the era of COVID‐19

D‐dimer is a fragment of crosslinked fibrin resulting from plasmin cleavage of fibrin clots and hence an indirect biomarker of the hemostatic system activation. Early in the coronavirus disease 2019 (COVID‐19) pandemic, several studies described coagulation disorders in affected patients, including...

Descripción completa

Detalles Bibliográficos
Autores principales: Auditeau, Claire, Khider, Lina, Planquette, Benjamin, Sanchez, Olivier, Smadja, David M., Gendron, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133433/
https://www.ncbi.nlm.nih.gov/pubmed/35664536
http://dx.doi.org/10.1002/rth2.12730
_version_ 1784713566562025472
author Auditeau, Claire
Khider, Lina
Planquette, Benjamin
Sanchez, Olivier
Smadja, David M.
Gendron, Nicolas
author_facet Auditeau, Claire
Khider, Lina
Planquette, Benjamin
Sanchez, Olivier
Smadja, David M.
Gendron, Nicolas
author_sort Auditeau, Claire
collection PubMed
description D‐dimer is a fragment of crosslinked fibrin resulting from plasmin cleavage of fibrin clots and hence an indirect biomarker of the hemostatic system activation. Early in the coronavirus disease 2019 (COVID‐19) pandemic, several studies described coagulation disorders in affected patients, including high D‐dimer levels. Consequently, D‐dimer has been widely used in not‐yet‐approved indications. Ruling out pulmonary embolism and deep vein thrombosis in patients with low or intermediate clinical suspicion is the main application of D‐dimer. D‐dimer is also used to estimate the risk of venous thromboembolism recurrence and is included in the ISTH algorithm for the diagnosis of disseminated intravascular coagulation. Finally, numerous studies identified high D‐dimer levels as a biomarker of poor prognosis in hospitalized patients with COVID‐19. This report focuses on validated applications of D‐dimer testing in patients with and without COVID‐19.
format Online
Article
Text
id pubmed-9133433
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-91334332022-06-04 D‐dimer testing in clinical practice in the era of COVID‐19 Auditeau, Claire Khider, Lina Planquette, Benjamin Sanchez, Olivier Smadja, David M. Gendron, Nicolas Res Pract Thromb Haemost Forum D‐dimer is a fragment of crosslinked fibrin resulting from plasmin cleavage of fibrin clots and hence an indirect biomarker of the hemostatic system activation. Early in the coronavirus disease 2019 (COVID‐19) pandemic, several studies described coagulation disorders in affected patients, including high D‐dimer levels. Consequently, D‐dimer has been widely used in not‐yet‐approved indications. Ruling out pulmonary embolism and deep vein thrombosis in patients with low or intermediate clinical suspicion is the main application of D‐dimer. D‐dimer is also used to estimate the risk of venous thromboembolism recurrence and is included in the ISTH algorithm for the diagnosis of disseminated intravascular coagulation. Finally, numerous studies identified high D‐dimer levels as a biomarker of poor prognosis in hospitalized patients with COVID‐19. This report focuses on validated applications of D‐dimer testing in patients with and without COVID‐19. John Wiley and Sons Inc. 2022-05-25 /pmc/articles/PMC9133433/ /pubmed/35664536 http://dx.doi.org/10.1002/rth2.12730 Text en © 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH). https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Forum
Auditeau, Claire
Khider, Lina
Planquette, Benjamin
Sanchez, Olivier
Smadja, David M.
Gendron, Nicolas
D‐dimer testing in clinical practice in the era of COVID‐19
title D‐dimer testing in clinical practice in the era of COVID‐19
title_full D‐dimer testing in clinical practice in the era of COVID‐19
title_fullStr D‐dimer testing in clinical practice in the era of COVID‐19
title_full_unstemmed D‐dimer testing in clinical practice in the era of COVID‐19
title_short D‐dimer testing in clinical practice in the era of COVID‐19
title_sort d‐dimer testing in clinical practice in the era of covid‐19
topic Forum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133433/
https://www.ncbi.nlm.nih.gov/pubmed/35664536
http://dx.doi.org/10.1002/rth2.12730
work_keys_str_mv AT auditeauclaire ddimertestinginclinicalpracticeintheeraofcovid19
AT khiderlina ddimertestinginclinicalpracticeintheeraofcovid19
AT planquettebenjamin ddimertestinginclinicalpracticeintheeraofcovid19
AT sanchezolivier ddimertestinginclinicalpracticeintheeraofcovid19
AT smadjadavidm ddimertestinginclinicalpracticeintheeraofcovid19
AT gendronnicolas ddimertestinginclinicalpracticeintheeraofcovid19